China is playing a long game in biopharma. And India needs to pay attention.
China has set an ambitious target: at least 25% of the world’s first-in-class drugs should originate in China by 2030.
At the same time, proposed technology-export restrictions seek to retain ownership of critical discovery platforms, including cell and gene therapies and siRNA technologies, while allowing international licensing partnerships.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
